Severe acute respiratory syndrome coronavirus 2 Spike protein Receptor Binding Domain (SARS-CoV-2 RBD)

The SARS-CoV-2 Receptor Binding Domain (RBD) is a critical component of the S1 subunit of the viral Spike (S) glycoprotein, responsible for mediating the virus's attachment to host cells by binding to the human Angiotensin-Converting Enzyme 2 (ACE2) receptor [1, 2]. As the primary interface for viral entry, the RBD is an immunodominant target for the host immune system and the primary focus of most therapeutic interventions, including mRNA and protein subunit vaccines as well as neutralizing monoclonal antibodies [15, 17]. Neutralizing agents function by binding to specific epitopes on the RBD, sterically hindering its ability to dock with ACE2 and effectively preventing infection [1, 4]. However, the RBD is also a site of rapid viral evolution, with mutations frequently emerging that enhance binding affinity to ACE2 or facilitate immune escape by altering antibody recognition sites [3, 7, 21]. Consequently, therapeutic development often involves combination therapies or broad-spectrum antibodies to overcome the challenge of shifting viral variants [1, 4]. Monitoring anti-RBD antibody titers serves as a key biomarker for assessing vaccine efficacy and prior exposure to the virus [18].

Other names

SARS-CoV-2 Spike RBDS-RBDSpike protein Receptor Binding DomainSpike protein S1 subunit RBDSevere acute respiratory syndrome coronavirus 2 Spike glycoprotein RBD

The primary mechanism of action for drugs targeting the SARS-CoV-2 RBD is neutralization, which involves binding to the domain to sterically block its interaction with the human Angiotensin-Converting Enzyme 2 (ACE2) receptor. This prevents the initial attachment of the virus to host cells, thereby inhibiting viral entry, membrane fusion, and subsequent infection [1, 2, 4, 15].